Conformation-specific antibodies to target amyloid β oligomers and their application to immunotherapy for Alzheimer's disease (Q38240609)

31 August 2017

title

Conformation-specific antibodies to target amyloid β oligomers and their application to immunotherapy for Alzheimer's disease (English)

1 reference

31 August 2017

0 references

1 reference

Kazuma Murakami

1

1 reference

31 August 2017

publication date

1 January 2014

1 reference

Bioscience, Biotechnology, and Biochemistry

31 August 2017

published in

1 reference

31 August 2017

volume

78

1 reference

31 August 2017

issue

8

1 reference

31 August 2017

page(s)

1293-1305

1 reference

Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Amyloid plaque core protein in Alzheimer disease and Down syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

The role of presenilin cofactors in the gamma-secretase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Extracellular phosphorylation of the amyloid β-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Potent amyloidogenicity and pathogenicity of Aβ43.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Formation and stabilization model of the 42-mer Abeta radical: implications for the long-lasting oxidative stress in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Enhanced pathologic properties of Dutch-type mutant amyloid beta-protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Metabolic regulation of brain Abeta by neprilysin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Alzheimer's disease: clinical trials and drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

A specific amyloid-beta protein assembly in the brain impairs memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Amyloid beta-protein assembly and Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Soluble Amyloid Aβ-(1–40) Exists as a Stable Dimer at Low Concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Distinct early folding and aggregation properties of Alzheimer amyloid-beta peptides Abeta40 and Abeta42: stable trimer or tetramer formation by Abeta42.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Plasticity in the human central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Oxidative stress in the progression of Alzheimer disease in the frontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

The redox chemistry of the Alzheimer's disease amyloid beta peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

SOD1 (copper/zinc superoxide dismutase) deficiency drives amyloid β protein oligomerization and memory loss in mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Drusen, choroidal neovascularization, and retinal pigment epithelium dysfunction in SOD1-deficient mice: a model of age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Skin atrophy in cytoplasmic SOD-deficient mice and its complete recovery using a vitamin C derivative.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Stimulation of the amyloidogenic pathway by cytoplasmic superoxide radicals in an Alzheimer's disease mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Formation of the 42-mer Amyloid β Radical and the Therapeutic Role of Superoxide Dismutase in Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Regulation of NMDA receptor trafficking by amyloid-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Disaggregation of Alzheimer beta-amyloid by site-directed mAb.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavin T1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Immunotherapy for Alzheimer's disease: hoops and hurdles

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Can Alzheimer disease be prevented by amyloid-beta immunotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not β-amyloid in cognitively normal older individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Evidence of fibril-like β-sheet structures in a neurotoxic amyloid intermediate of Alzheimer's β-amyloid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Conformation-dependent anti-amyloid oligomer antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Conformation-dependent antibodies target diseases of protein misfolding

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

A fibril-specific, conformation-dependent antibody recognizes a subset of Abeta plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Conformation-dependent oligomers in cerebrospinal fluid of presymptomatic familial Alzheimer's disease mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Isolation and characterization of patient-derived, toxic, high mass amyloid beta-protein (Abeta) assembly from Alzheimer disease brains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Two Distinct Amyloid β-Protein (Aβ) Assembly Pathways Leading to Oligomers and Fibrils Identified by Combined Fluorescence Correlation Spectroscopy, Morphology, and Toxicity Analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Amyloid beta oligomers (A beta(1-42) globulomer) suppress spontaneous synaptic activity by inhibition of P/Q-type calcium currents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Structure-based design of conformation- and sequence-specific antibodies against amyloid β.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Motif-grafted antibodies containing the replicative interface of cellular PrP are specific for PrPSc

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Rational design of potent domain antibody inhibitors of amyloid fibril assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Molecular basis of -amyloid oligomer recognition with a conformational antibody fragment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

3D structure of Alzheimer's amyloid-beta(1-42) fibrils

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

A structural model for Alzheimer's beta -amyloid fibrils based on experimental constraints from solid state NMR

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Molecular structure of amyloid fibrils: insights from solid-state NMR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Monoclonal antibody against the turn of the 42-residue amyloid β-protein at positions 22 and 23

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's A beta(1--42) and A beta(25--35).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Analysis of the secondary structure of beta-amyloid (Abeta42) fibrils by systematic proline replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

The toxic conformation of the 42-residue amyloid beta peptide and its relevance to oxidative stress in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

The turn formation at positions 22 and 23 in the 42-mer amyloid beta peptide: the emerging role in the pathogenesis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Non-toxic conformer of amyloid β may suppress amyloid β-induced toxicity in rat primary neurons: implications for a novel therapeutic strategy for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Toxicity in rat primary neurons through the cellular oxidative stress induced by the turn formation at positions 22 and 23 of Aβ42.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Neurotoxicity and physicochemical properties of Abeta mutant peptides from cerebral amyloid angiopathy: implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Intracellular amyloid-beta in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Intraneuronal amyloid β oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Intraneuronal Abeta42 accumulation in human brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Intracellular amyloid beta-protein as a therapeutic target for treating Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Early accumulation of intracellular fibrillar oligomers and late congophilic amyloid angiopathy in mice expressing the Osaka intra-Aβ APP mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Pathways by which Abeta facilitates tau pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Natural products as a source of Alzheimer's drug leads

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Lysine-Specific Molecular Tweezers Are Broad-Spectrum Inhibitors of Assembly and Toxicity of Amyloid Proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Site-specific inhibitory mechanism for amyloid β42 aggregation by catechol-type flavonoids targeting the Lys residues

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

A sensitive aβ oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Macromolecular permeability across the blood-nerve and blood-brain barriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

Amyloid-beta in Alzheimer Disease: The Null versus the Alternate Hypotheses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09168451.2014.940275

10.1080/09168451.2014.940275

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference